BAD (BCL2-associated agonist of cell death) is a pro-apoptotic member of the BCL-2 family that plays a critical role in regulating mitochondrial-dependent apoptosis. It functions as a key initiator of programmed cell death and is implicated in various neurodegenerative diseases where excessive neuronal apoptosis occurs.
| Property |
Value |
| Gene Symbol |
BAD |
| Protein |
BAD protein |
| Chromosomal Location |
11q13.1 |
| NCBI Gene ID |
573 |
| UniProt ID |
Q92934 |
| Aliases |
BCL2L8, BBC2 |
BAD is a BH3-only pro-apoptotic BCL-2 family member:
- Apoptosis initiation: Directly activates BAX/BAK or inhibits anti-apoptotic BCL-2 proteins
- Mitochondrial regulation: Controls mitochondrial outer membrane permeabilization (MOMP)
- Growth factor signaling: Integrates survival signals from cytokines, growth factors
- Phosphorylation: Serine phosphorylation regulates its pro- vs anti-apoptotic activity
- Tissue expression: Broad expression, high in lymphoid tissues
- Neuronal apoptosis: BAD mediates amyloid-beta induced neuronal death
- Tau pathology: BAD activation linked to tau-induced synaptic loss
- Synaptic failure: Contributes to synapse elimination in AD
- Therapeutic target: BAD inhibitors may protect neurons
- Dopaminergic neuron death: BAD mediates apoptosis in substantia nigra neurons
- α-synuclein toxicity: BAD activation in response to α-synuclein aggregation
- Mitochondrial dysfunction: Interacts with PINK1/Parkin pathway
- Neuroprotection: BAD knockout mice show reduced dopaminergic loss
- Excitotoxic apoptosis: BAD involved in glutamate-induced neuronal death
- Mutant huntingtin: Increases BAD pro-apoptotic activity
- Therapeutic potential: BAD inhibitors show promise in HD models
- Motor neuron apoptosis: BAD contributes to motor neuron death
- Glutamate excitotoxicity: Links excitotoxic signals to mitochondrial apoptosis
- Ischemic neuronal death: BAD activation in cerebral ischemia
- Therapeutic neuroprotection: BAD inhibition reduces infarct size in models
Stress signals → BAD dephosphorylation → Mitochondrial translocation
↓
BAX/BAK activation → MOMP → Cytochrome c release
↓
Apoptosome formation → Caspase-9 activation
↓
Caspase cascade → Cell death
| Regulator |
Interaction |
Effect |
| BCL2 |
Sequestration |
Inhibits pro-apoptotic function |
| BCL2L1 (BCL-XL) |
Sequestration |
Inhibits pro-apoptotic function |
| AKT/PKB |
Serine phosphorylation |
Inhibits pro-apoptotic function |
| MAPK |
Serine phosphorylation |
Context-dependent |
| Interactor |
Interaction Type |
Functional Effect |
| BCL2 |
BH3 binding |
Anti-apoptotic sequestration |
| BCL2L1 |
BH3 binding |
Anti-apoptotic sequestration |
| BAX |
Direct activation |
Pore formation |
| BAK1 |
Direct activation |
Pore formation |
| MCL1 |
BH3 binding |
Anti-apoptotic |
| AKT1 |
Phosphorylation |
Inactivation |
- BAD mimetics: BH3 mimetics that block BAD's pro-apoptotic function
- Indirect inhibitors: BCL-2/BCL-XL inhibitors (navitoclax, venetoclax) indirectly inhibit BAD
- Kinase inhibitors: AKT activators could indirectly inhibit BAD
- Direct BAD inhibitors not in clinical trials for neurodegeneration
- BCL-2 family inhibitors approved for cancer, being explored for neuroprotection
- Gene therapy approaches to reduce BAD expression in development